Navigation Links
Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone
Date:1/10/2011

tics in general, and the TOMM40 biomarker specifically, to identify at-risk individuals who may be candidates for treatment in a pharmacogenetics-assisted clinical trial," said Dr. Roses. "We look forward to working with a partner like Takeda, who shares our commitment to reducing the prevalence of Alzheimer's disease over the next 20-30 years."

Alzheimer's disease is a degenerative brain disease characterized by a progressive decline in memory, thinking, comprehension, calculation, language, learning capacity and judgment sufficient to impair personal activities of daily living. Approximately 18 million people worldwide are currently suffering from Alzheimer's disease, and the rate of occurrence doubles every five years for those between 65 and 85 years of age.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

About Zinfandel Pharmaceuticals

Zinfandel Pharmaceuticals, based in Durham, NC, is a privately held company dedicated to using pharmacogenetics to improve prediction of risk for Alzheimer's disease and thus facilitate the development of effective therapies.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited; Zinfandel Pharmaceutcals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
2. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Sales Horizons, a leader in sales ... training programs for companies engaged in complex B2B sales. ... thousands of salespeople over 25 years in market-leading Fortune ... be customized to address the unique sales challenges of ... training program consists of two parts: Mastering the ...
(Date:7/30/2014)... 30, 2014 BCC Research ( http://www.bccresearch.com ... for Enzymes in Industrial Applications , the global market ... $7.1 billion by 2018, registering a five-year compound annual ... to be recorded in the detergent enzyme segment with ... Enzyme technology has influenced almost every sector of industrial ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... MARLBOROUGH, Mass. , July 30, 2014 ... RXII ), a biotechnology company focused on ... major unmet medical needs using RNA-targeted technologies, ... study (RXI-109-1402) with RXI-109, for the reduction ... scar revision surgery, has been initiated. ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... FRANCISCO, Calif., Jan. 4 Cerimon,Pharmaceuticals, Inc. announced ... Counsel, a newly established position, and Vice President ... global life sciences,executive and corporate attorney with broad ... in the US and,Europe. In the business development ...
... efficacy in treatment of multi-drug ... resistant infections -, ... "Company"), a biopharmaceutical company focused on the,development of novel antibiotics for ... patients in two,separate Phase 2 clinical trials. The studies will evaluate ...
... and biotechnology ... expertise, BOSTON, Jan. 3 Observant LLC has ... for research excellence,and a commitment to client service. John ... firm as Vice President. Dr. Hartman,s,research has focused on ...
Cached Biology Technology:Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 3Observant LLC Expands Senior Management Team 2
(Date:7/30/2014)... July 30, 2014 NexID Biometrics ... liveness detection solutions for the biometric authentication industry, ... consortium revolutionizing online authentication with standards for strong ... , "The decision to join FIDO Alliance stems ... pervasive in use. We believe the FIDO Alliance ...
(Date:7/30/2014)... Scientists are searching through a massive collection of 20-million-year-old ... years ago, and the effort is yielding fresh insights ... , When the collection is fully curated, a task ... largest unbiased Dominican amber collection in the world, the ... thus far is that of a pygmy locust, a ...
(Date:7/30/2014)... in cancer treatment has been shown to relieve ... for neural transmission between the peripheral and central ... Institute of Radiation Medicine, Chinese Academy of Medical ... into rat dorsal root ganglia (DRG) to provide ... radioactivity (0, 14.8, 29.6 MBq) were implanted separately ...
Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2Decades-old amber collection offers new views of a lost world 2
... 21 February 2011 Elsevier, a world-leading publisher ... services, and TAIR - The Arabidopsis Information Resource, ... elements of scientific research. All articles on Elsevier,s ... genes and use AGI codes (e.g. AT4G32520) will ...
... Researchers at Albert Einstein College of Medicine ... to protect against an increasingly common and particularly deadly form ... tested in an animal model, are reported in a paper ... Pneumococcal pneumonia can occur when the lungs are ...
... heart diseases affect approximately one in 100 patients, making ... number-one cause of pediatric deaths. Now a new ... cardiac muscle damage in a mouse model of the congenital ... treatment for this rare condition, but also demonstrates the importance ...
Cached Biology News:Vaccine made with synthetic gene protects against deadly pneumonia 2Vaccine made with synthetic gene protects against deadly pneumonia 3Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 2Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 3
... Gene Expression (SAGE) is a powerful ... a cost-effective outsourcing solution for sequencing ... Agencourt's SAGE sequencing service provides our ... long Phred20 read lengths (40 SAGE ...
... Sciences can provide custom microplate coating using advanced automated high ... of plate formats. We can also accommodate virtually any lot ... 0.5-320 L):, , 8 ... well microplate, 384 well microplate, ...
... ) The antibody is preadsorbed to remove any ... buffered aqueous glycerol solution A solution ... 2+ and Ca 2+ ), pH 7.3 ... (IgG, protease free) and 0.05% sodium azide A ...
... Cytometry The Guava EasyCyte system is ... multiparameter cytometer with built-in 96-well microplate sampling ... plates of cells and compounds quickly and ... tubes or having the carryover issues found ...
Biology Products: